鲁军
一、个人简介
鲁军，成都中医药大学教授/博士生导师；香港浸会大学中医药学院博士/博士后，任职于成都中医药大学药学院。四川省高层次引进人才，省部级优秀人才计划入选者，四川省杰出青年科技人才。在nature aging, nature communications, european journal of medicinal chemistry, pharmacological research等国际期刊发表sci论文50余篇，申请多项中国和美国发明专利并已授权专利8项。主持国家自然基金面上项目、青年项目、四川省杰出青年基金及地区基金10余项。
m6米乐安卓版下载的联系方式：ljaaa111@163.com
研究方向：
1药物化学及药物递送方向
靶向抗肿瘤功能性大分子（包括核酸、多肽、多糖等具有特殊功能性的大分子）-活性天然药物偶联物的设计、合成以及药理学评价；
多功能自组装纳米药物的设计、合成以及药理学评价。
2 有机化学及药物合成方向
基于增效减毒的目的，对具有潜在生物活性的中药单体成分或是高毒性的天然药物成分进行结构修饰，获取新型药物分子，并进行药理学评价；
基于手性小分子催化剂，开发新型催化剂以及构建新的合成方法，用于建立具有开发和应用前景的药物分子库。
3 药理学方向
针对肿瘤、炎症等相关疾病开发的新型药物分子或是活性天然产物，评价其生物活性并阐明作用机制。
二、代表性成果（可含承担项目、发表论文、论著、获奖等）
1.国家自然科学基金委员会，面上项目，82273812，核酸适配体-多价喜树碱偶联物的设计、合成及其egfr介导的靶向抗肿瘤活性研究，2023-01-01至2026-12-31，在研，主持
2.四川省自然科学基金，杰出青年科学基金，23nsfjq0099，gsh驱动智能型egfr核酸适配体多价喜树碱偶联物“精准狙击”非小细胞肺癌的研究，2023-01至 2026-12，在研，主持
2021~2022年代表作：
1.yiru pu, yi zuo, jie ling, meimei li, hui huang, jun lu*. carbene-catalyzed kinetic resolution of bispirooxindoles: selective lactam amidation and access to challenging chiral scaffolds. organic chemistry frontiers.
2.yao chen, jirui yang, yi zuo, chaozheng zhang, yiru pu, qing ren, xiao li, yunqian huang, hui huang, huan yang, ouyang you, xila xia, aiping lu, sanjun shi, yun deng, jun lu*. voacamine is a novel inhibitor of egfr exerting oncogenic activity against colorectal cancer through the mitochondrial pathway. pharmacological research, 2022, 184, 106415.
3.meimei li, hui huang, wanrong tian, yiru pu, yun deng, jun lu*. a close look into the biological and synthetic aspects of fused pyrazole derivatives. european journal of medicinal chemistry, 2022: 114739.
4.meimei li, hui huang, wanrong tian, yiru pu, chaozheng zhang, jirui yang, qing ren, feiyan tao, yun deng, jun lu*. construction of multi-substituted pyrazoles via potassium carbonate-mediated [3 2] cycloaddition of in situ generated nitrile imines with cinnamic aldehydes. rsc advances, 2022, 12, 13087-13092.
5.yi zuo, chaozheng zhang, qing ren, yao chen, xiao li, jirui yang, hongxiang li, wentao tang, hingman ho, chen sun, meimei li, bo ren, yun deng, maolin wang, jun lu*. activation of mitochondrial-associated apoptosis signaling pathway and inhibition of pi3k/akt/mtor signaling pathway by voacamine suppress breast cancer progression. phytomedicine, 2022, 99, 154015.
6.qing ren, meimei li, yun deng, aiping lu, jun lu*. triptolide delivery: nanotechnology-based carrier systems to enhance efficacy and limit toxicity. pharmacological research, 2021, 165, 105377.
7.meimei li, yun deng, jun lu*. dracaenone, a novel type of homoisoflavone: natural source, biological activity and chemical synthesis[j]. current organic chemistry, 2022, 26, 887-897.
8.yuzhi wang, zhaohai pan, xiaolan cheng, kai zhang, xin zhang, yao qin, jiaojiao fan, ting yan, tao han, kwok keung shiu, sam chun-kithau, nai kimak, daniel w.j.kwong, xiaona liu, minjing li, guowei deng, qiusheng zheng, jun lu*, defang li*. a red-light-activated sulfonamide porphycene for highly efficient photodynamic therapy against hypoxic tumor. european journal of medicinal chemistry. 2021, 209, 11286.
9.zhaohai pan, jiaojiao fan, qi xie, xin zhang, wen zhang, qing ren, minjing li, qiusheng zheng, jun lu*, defang li*. novel sulfonamide porphyrin tbpos-2oh used in photodynamic therapy for malignant melanoma. biomedicine & pharmacotherapy, 2021, 133, 111042.
10.meimei li, xiaozhen chen, yun deng, jun lu*. recent advances of n-heterocyclic carbenes in the applications of constructing carbo-and heterocyclic frameworks with potential biological activity. rsc advances, 2021, 11, 38060-38078.
11.maolin wang, xingsheng shu, meiqi li, yilin zhang, youli yao, xiaoyan huang, jianna li, pengfei wei, zhendan he, jun lu*, ying ying*. novel strategy conjugating pd-l1 polypeptide with doxorubicin alleviates chemotherapeutic resistance and enhances immune response in colon cancer. frontiers in oncology, 2021, 11, 737323.
12.jin liu#, xiaohao wu#, jun lu#, guangxin huang#, lei dang, huarui zhang, chuanxin zhong, zongkang zhang, dijie li, fangfei li, chao liang, yuanyuan yu, bao-ting zhang, lin chen, aiping lu, ge zhang exosomal transfer of osteoclast-derived mirnas to chondrocytes contributes to osteoarthritis progression. nature aging, 2021, 1, 1-17.